2023

Collaboration aims to accelerate automation of rapid NGS testing February 18, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company. As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected, […]

In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We’ve made substantial advancements and improved access to precision oncology solutions globally.  Here is a summary of select key achievements in 2024:  FDA Approval of oncoReveal® CDx In April, Pillar

Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) for its proprietary OncoKB™ precision medicine knowledgebase.  OncoKB™ is the first somatic human variant database to receive FDA

Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP).  The assay, branded as MSK-React, is based on a new panel from Pillar Biosciences, recently launched as

Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting in Vancouver, BC, Canada. The company and scientific collaborators will collectively present ten studies and host three corporate workshops, showcasing their latest advancements in Next-Generation Sequencing (NGS) technology and oncology

Natick, MA – October 24, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced that they have been granted a unique CPT® Proprietary Laboratory Analyses (PLA) code 0523U from the American Medical Association (AMA) for their FDA approved oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD) NGS kit. oncoReveal™ CDx is a NGS

Enables content for newly launched Illumina MiSeq™ i100 and expands Illumina oncology panel portfolio to include targeted liquid biopsy panels Natick, MA – October 16, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has today announced an expansion of their existing partnership with Illumina, through which a broader portfolio of Pillar’s oncoReveal™ NGS panels will now be

Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions. Natick, MA – September 10, 2024 – Pillar Biosciences, Inc., has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling

Natick, MA – August 27, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy. A team at New York’s Memorial Sloan

Natick, MA – July 30, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the first national molecular reference laboratory to verify and launch oncoReveal™ CDx. The oncoReveal™ CDx pan-cancer solid tumor IVD kit has been FDA PMA approved for general tumor profiling for 22 clinically